{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:45:08Z","timestamp":1791726308681,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.cmi.2021.02.006","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:32:59Z","timestamp":1613561579000},"page":"915.e5-915.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["In\u00a0vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures"],"prefix":"10.1016","volume":"27","author":[{"given":"Aina","family":"Mesquida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Reigadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"S\u00e1nchez-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.02.006_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.02.006_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bjm.2016.09.006","article-title":"Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates","volume":"48","author":"Brandolt","year":"2017","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.cmi.2021.02.006_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/mmy\/myx099","article-title":"Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals","volume":"56","author":"Wu","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2021.02.006_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00161-17","article-title":"Differential Activity of the oral glucan synthase inhibitor scy-078 against wild-type and echinocandin-resistant strains of Candida Species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.02.006_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2021.02.006_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-19","article-title":"In\u00a0Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as determined by EUCAST methodology and comparison with activity against C.\u00a0albicans and C.\u00a0glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.02.006_bib7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in\u00a0vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.02.006_bib8","doi-asserted-by":"crossref","first-page":"e02611","DOI":"10.1128\/AAC.02611-18","article-title":"A\u00a0novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (Formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis","volume":"63","author":"Larkin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.02.006_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.cmi.2021.02.006_bib10","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1111\/j.1469-0691.2012.03880.x","article-title":"EUCAST-AFST EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.02.006_bib11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.02.006_bib12","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.02.006_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.resmic.2015.02.009","article-title":"Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China","volume":"166","author":"Liu","year":"2015","journal-title":"Res Microbiol"},{"key":"10.1016\/j.cmi.2021.02.006_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fcimb.2020.00166","article-title":"Genotyping reveals high clonal diversity and widespread genotypes of Candida Causing Candidemia at distant geographical areas","volume":"10","author":"Guinea","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2021.02.006_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/genetics\/155.2.945","article-title":"Inference of population structure using multilocus genotype data","volume":"155","author":"Pritchard","year":"2000","journal-title":"Genetics"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:28:07Z","timestamp":1761118087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1198743X21000811"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.02.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}